SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Anti-HepA [HA1] Bulk Size Ab00920-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

Isotype and Format: Human IgG1, Fc Silent™, Kappa
Clone Number: HA1
Alternative Name(s) of Target: HAV; Hepatitis A virus; Hep-A
UniProt Accession Number of Target Protein:
Published Application(s): ELISA;, Radioimmunofocus inhibition assays
Published Species Reactivity: Virus (HepA)
Immunogen: Generated mAbs to HAV by phage display of the antibody library generated from the peripheral blood lymphocytes of immune donor recovered from hepatitis A. The cDNAs encoding the immunoglobulin gamma1 Fd and kappa light chains were synthesized from total RNA of the PBLs of the HAV-immune donors and cloned into a phage display vector to construct a combinatorial library of clones. The phage-displayed Fab library was panned four times against HAV. Analysis of the antigen-binding activities of the pooled phages after each round of the panning indicated that HAV-binding phage clones were almost selected after the third round of panning. Finally, 24 phage clones after the fourth panning were selected, and the gene III fragment was removed to produce soluble Fab. Analysis of the antigen-binding activities of the 24 Fab clones by ELISA revealed that 22 clones were positive in HAV binding, which could be grouped into 4 different clones; HA1, HA6, HA9, and HA12.
Specificity: Reactive to both 14S and 70S HAV particles. HA1 and HA12 recognise distinct epitopes, whereas HA6 recognises an epitope that overlaps with that of HA1 or HA12. Competitive binding assays have shown that all of these mAbs overlap with the epitopes bound by murine mAb in a single immunodominant neutralisation site on the HAV capsid.
Application Notes: HA1 has been shown to have HAV-neutralising activity through its use in radioimmunofocus inhibition assays (Kim 2003).
Antibody First Published in: Kim SJ et al. Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display Virology. 2004 Jan 20;318(2):598-607. PMID:14972527
Note on publication: Describes the generation and characterisation of anti-HAV mAbs.

Product Form

Size: 1 mg Purified antibody in bulk size.
Purification:

Protein A affinity purified
Supplied In: PBS only.
Storage Recommendation: Store at 4^{o}C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20^{o}C.
Concentration: 1 mg /ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.